UT-155 NEW
| Price | $93 | $228 | $363 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: UT-155 | CAS No.: 2031161-35-8 |
| Purity: 98.94% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | UT-155 |
| Description | UT-155 is a selective and potent antagonist of the androgen receptor (AR) with a binding affinity (Ki) of 267 nM for the AR ligand-binding domain (AR-LBD). |
| In vitro | UT-155 binds to the AR-LBD (Ki: 267 nM) and potently inhibits R1881-induced wildtype AR transactivation with 6-10-fold higher potency than enzalutamide. While UT-155 antagonizes both wildtype and mutant ARs comparably, enzalutamide's efficacy is halved against the W742L mutant AR. In LNCaP cells, UT-155 inhibits PSA and FKBP5 gene expression induced by 0.1 nM R1881 at concentrations between 10 and 100 nM, demonstrating 5-10 times better efficacy than enzalutamide. |
| In vivo | Consistent with its anti-proliferative effects in vitro, UT-155 significantly inhibits the growth of 22RV1 xenografts by 53%, while enzalutamide has no effect. In UT-155-treated animals, tumor weights, PSA levels, and expression of AR and AR-SV are significantly reduced. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 0.1 mg/mL (insoluble) DMSO : 130 mg/mL (320.71 mM) |
| Keywords | Inhibitor | UT155 | inhibit | Androgen Receptor | UT-155 | UT 155 |
| Inhibitors Related | Dehydroisoandrosterone 3-acetate | Bicalutamide | 2,2,5,7,8-Pentamethyl-6-Chromanol | S-23 | Bavdegalutamide | Enzalutamide | Adrenosterone | Allura Red AC | SK33 | Sunset Yellow FCF | Ostarine | Flutamide |
| Related Compound Libraries | Nuclear Receptor Compound Library | Bioactive Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Prostate Cancer Compound Library | Endocrinology-Hormone Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Transcription Factor-Targeted Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $48.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-17 | |
| $1980.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $0.00/10mg |
VIP1Y
|
ShenZhen H&D Pharmaceutical Technology Co., LTD
|
2024-04-15 | |
| $93.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $1000.00/1Bottle |
VIP4Y
|
Wuhan Nutra Biotechnology Co.,Ltd
|
2022-06-24 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY